Literature DB >> 28068461

A New Prediction Model for Evaluating Treatment-Resistant Depression.

Alexander Kautzky1, Pia Baldinger-Melich1, Georg S Kranz1, Thomas Vanicek1, Daniel Souery2, Stuart Montgomery3, Julien Mendlewicz4, Joseph Zohar5, Alessandro Serretti6, Rupert Lanzenberger1, Siegfried Kasper7,1.   

Abstract

OBJECTIVE: Despite a broad arsenal of antidepressants, about a third of patients suffering from major depressive disorder (MDD) do not respond sufficiently to adequate treatment. Using the data pool of the Group for the Study of Resistant Depression and machine learning, we intended to draw new insights featuring 48 clinical, sociodemographic, and psychosocial predictors for treatment outcome.
METHOD: Patients were enrolled starting from January 2000 and diagnosed according to DSM-IV. Treatment-resistant depression (TRD) was defined by a 17-item Hamilton Depression Rating Scale (HDRS) score ≥ 17 after at least 2 antidepressant trials of adequate dosage and length. Remission was defined by an HDRS score < 8. Stepwise predictor reduction using randomForest was performed to find the optimal number for classification of treatment outcome. After importance values were generated, prediction for remission and resistance was performed in a training sample of 400 patients. For prediction, we used a set of 80 patients not featured in the training sample and computed receiver operating characteristics.
RESULTS: The most useful predictors for treatment outcome were the timespan between first and last depressive episode, age at first antidepressant treatment, response to first antidepressant treatment, severity, suicidality, melancholia, number of lifetime depressive episodes, patients' admittance type, education, occupation, and comorbid diabetes, panic, and thyroid disorder. While single predictors could not reach a prediction accuracy much different from random guessing, by combining all predictors, we could detect resistance with an accuracy of 0.737 and remission with an accuracy of 0.850. Consequently, 65.5% of predictions for TRD and 77.7% for remission can be expected to be accurate.
CONCLUSIONS: Using machine learning algorithms, we could demonstrate success rates of 0.737 for predicting TRD and 0.850 for predicting remission, surpassing predictive capabilities of clinicians. Our results strengthen data mining and suggest the benefit of focus on interaction-based statistics. Considering that all predictors can easily be obtained in a clinical setting, we hope that our model can be tested by other research groups. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28068461     DOI: 10.4088/JCP.15m10381

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases.

Authors:  Michele Fornaro; Andrea Fusco; Stefano Novello; Pierluigi Mosca; Annalisa Anastasia; Antonella De Blasio; Felice Iasevoli; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2020-05-15       Impact factor: 4.157

Review 2.  Medications for substance use disorders (SUD): emerging approaches.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Expert Opin Emerg Drugs       Date:  2017-10-30       Impact factor: 4.191

3.  Using a machine learning approach to investigate factors associated with treatment-resistant depression among adults with chronic non-cancer pain conditions and major depressive disorder.

Authors:  Drishti Shah; Wanhong Zheng; Lindsay Allen; Wenhui Wei; Traci LeMasters; Suresh Madhavan; Usha Sambamoorthi
Journal:  Curr Med Res Opin       Date:  2021-03-24       Impact factor: 2.580

4.  Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.

Authors:  Drishti Shah; Lindsay Allen; Wanhong Zheng; Suresh S Madhavan; Wenhui Wei; Traci J LeMasters; Usha Sambamoorthi
Journal:  Pharmacoeconomics       Date:  2021-04-27       Impact factor: 4.558

5.  The effect of co-morbid anxiety on remission from depression for people participating in a randomised controlled trial of the Friendship Bench intervention in Zimbabwe.

Authors:  Melanie Amna Abas; Helen Anne Weiss; Victoria Simms; Ruth Verhey; Simbarashe Rusakaniko; Ricardo Araya; Dixon Chibanda
Journal:  EClinicalMedicine       Date:  2020-05-27

6.  FT4 and TSH, relation to diagnoses in an unselected psychiatric acute-ward population, and change during acute psychiatric admission.

Authors:  Yuki Sakai; Valentina Iversen; Solveig Klæbo Reitan
Journal:  BMC Psychiatry       Date:  2018-07-28       Impact factor: 3.630

7.  Finding factors that predict treatment-resistant depression: Results of a cohort study.

Authors:  M Soledad Cepeda; Jenna Reps; Patrick Ryan
Journal:  Depress Anxiety       Date:  2018-05-22       Impact factor: 6.505

Review 8.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

9.  Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data.

Authors:  Dekel Taliaz; Amit Spinrad; Ran Barzilay; Zohar Barnett-Itzhaki; Dana Averbuch; Omri Teltsh; Roy Schurr; Sne Darki-Morag; Bernard Lerer
Journal:  Transl Psychiatry       Date:  2021-07-08       Impact factor: 6.222

10.  The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology

Authors:  Hee-Ju Kang; Ju-Wan Kim; Seon-Young Kim; Sung-Wan Kim; Hee-Young Shin; Myung-Geun Shin; Jae-Min Kim
Journal:  Psychiatry Investig       Date:  2018-04-05       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.